A home administration route for the subcutaneous injection omacetaxine mepesuccinate (Synribo) was approved by the FDA for use in patients with chronic or accelerated phase chronic myeloid leukemia (CML) who are resistant or intolerant to treatment with tyrosine kinase inhibitors.
We were thrilled to cohost the Colorectal Cancer Survivor Panel Lunch & Learn at the recent OMG! Cancer Summit for Young Adults with our friends at Chris4Life.
ASCO panel develops screening and management guidelines
The Leukemia & Lymphoma Society (LLS) is pleased to present the following updated publications for patients and caregivers
No one likes going to the dentist, but l'm thankful I did.
The FDA has granted an accelerated approval to the next-generation ALK inhibitor ceritinib as a treatment for patients with ALK-positive metastatic non-small cell lung cancer following progression on crizotinib.
I have been living with stage IV lung cancer for three years, not because I have the disease, but because my husband does.
Patients who received adjuvant chemotherapy as treatment for their breast cancer were less likely to be working after their treatment compared with patients who were not treated with adjuvant chemotherapy.
Failure to identify and treat symptoms reduces quality of life.
An update from the Foundation for Women's Cancer and Society of Gynecologic Oncology
Take it from young women who've been there-sometimes you just want to talk to someone who's been there, too.
When parents are involved in the care of a child with cancer, they experience both positive and negative changes in their relationships, communication, stress, and their roles.
The FDA has granted the first-ever approval for a diagnostic test alternative to Pap smear, the cobas HPV Test, despite objections from a number of organizations and healthcare providers.
Cancer patients felt more satisfied with their radiation treatment when they remained active in treatment decisions, according to a study conducted by researchers from the Perelman School of Medicine at the University of Pennsylvania.
No agents are recommended for the prevention of CIPN.
The FDA has approved ramucirumab (Cyramza) as a single-agent treatment for patients with unresectable or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma following fluoropyrimidine- or platinum-containing therapy.
The Cancer Support Community has a special resource for patients with every type of cancer to share their thoughts and concerns with others who are sharing similar experiences.
Imerman Angels was created on the belief that no one should have to face cancer alone.
After recently giving notice at the company where I have worked for almost 10 years, I was disturbed to hear about a comment made in passing by another manager.
The FDA has approved ofatumumab (Arzerra) plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia (CLL) who are considered inappropriate for treatment with the chemotherapy fludarabine.
Adult survivors of childhood cancer face significant health problems as they age and are five times more likely than their siblings to develop new cancers, heart, and other serious health conditions beyond the age of 35 years
The Centers for Medicare & Medicaid Services (CMS) is piloting a new Medicare Choices Care Model, designed to provide a new option for Medicare beneficiaries to concurrently receive palliative care services from hospice providers while also receiving services from curative care providers.
Benefits seen when intake is 7 or more servings per day.
The American Society of Clinical Oncology (ASCO) announced today three new evidence-based clinical practice guidelines on neuropathy, fatigue, and depression and anxiety in cancer survivors, the first three in a planned series of ASCO guidelines on survivorship care.
Patients who had a high Body Mass Index (BMI) before being diagnosed with colorectal cancer had an increased risk of death after diagnosis, even if their tumor harbored the microsatellite instability (MSI) marker
Women with irregular menstrual cycles have a 2.4-fold increased risk of death from ovarian cancer, according to a large, prospective study presented at the 2014 AACR Annual Meeting.
Continued monitoring of long-term effects of these drugs is warranted.
Palbociclib, an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, more than doubled progression-free survival (PFS) when used in combination with letrozole for patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer
Women who took the fertility drugs clomiphene citrate (Clomid) or gonadotropins did not experience an increased risk for breast cancer compared with women who were not treated with those medications, according to a 30-year follow-up study published in the April issue of Cancer Epidemiology, Biomarkers & Prevention.
Study from one cancer center shows low knowledge and comfort levels.
